This fast track antibody is not yet fully characterized. It is subject to these terms and conditions

Overview

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
  • Storage buffer
    pH: 7.30
    Preservative: 0.02% Sodium azide
    Constituents: 99% Tris buffered saline, 0.5% BSA
  • Concentration information loading...
  • Purity
    Immunogen affinity purified
  • Purification notes
    Purified from Goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
  • Clonality
    Polyclonal
  • Isotype
    IgG
  • Research areas

Applications

Fast track antibodies constitute a diverse group of products that have been released to accelerate your research, but are not yet fully characterized. They have all been affinity purified and show high titre values against the immunizing peptide (by ELISA). Fast track terms of use

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 195 kDa.

Preliminary experiments in Mouse and Rat Eye lysates gave no specific signal but low background (at antibody concentration up to 1µg/ml).

Target

  • Function
    May play an integral structural role in elastic-fiber architectural organization and/or assembly.
  • Tissue specificity
    Expressed in lung, weakly expressed in heart, placenta, liver and skeletal muscle.
  • Involvement in disease
    Defects in LTBP2 are the cause of primary congenital glaucoma type 3D (GLC3D) [MIM:613086]. An autosomal recessive form of primary congenital glaucoma (PCG). PCG is characterized by marked increase of intraocular pressure at birth or early childhood, large ocular globes (buphthalmos) and corneal edema. It results from developmental defects of the trabecular meshwork and anterior chamber angle of the eye that prevent adequate drainage of aqueous humor.
    Defects in LTBP2 are the cause of microspherophakia (MCSPH) [MIM:251750]. It is a rare disease characterized by smaller and more spherical lenses than normal bilaterally, an increased anteroposterior thickness of the lens and highly myopic eyes. Lens dislocation or subluxation may occur, leading to defective accommodation.
  • Sequence similarities
    Belongs to the LTBP family.
    Contains 20 EGF-like domains.
    Contains 4 TB (TGF-beta binding) domains.
  • Domain
    Associates covalently with small latent TGF-beta complex via Repeat B and Repeat C.
  • Post-translational
    modifications
    Contains hydroxylated asparagine residues.
  • Cellular localization
    Secreted. Localized in nuchal ligament and aorta to the fibrillin-containing, microfibrillar component of elastic fibers.
  • Information by UniProt
  • Database links
  • Alternative names
    • C14orf141 antibody
    • Chromosome 14 open reading frame 141 antibody
    • Latent TGF beta binding protein 2 antibody
    • Latent transforming growth factor beta binding protein 2 antibody
    • Latent-transforming growth factor beta-binding protein 2 antibody
    • LTBP 2 antibody
    • LTBP 3 antibody
    • LTBP-2 antibody
    • Ltbp2 antibody
    • LTBP2_HUMAN antibody
    • LTBP3 antibody
    • MSTP 031 antibody
    • MSTP031 antibody
    see all

References

ab121005 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab121005.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up